You are here

P&T News

December 26

An SGLT2 inhibitor and two fixed-dose combinations will be available in January and February 2018

December 21

FDA announces that four studies showed no increased risk of death
Accelerated approval for neoadjuvant use also converted to full approval
Recurrence-free survival superior to Yervoy in trial

December 20

Pfizer drug was previously indicated as second-line therapy
Approval granted well in advance of predicted PDUFA date

December 19

Legal dispute between Shire and Roche over “patent infringement” began in May
Ultragenyx will present voucher to Novartis upon closing of transaction
Luxturna is first gene therapy to target a disease caused by mutations in a specific gene
Decline may stem from trust in physicians or effort needed to obtain exemptions
Drug lowers intraocular pressure in open-angle glaucoma or ocular hypertension

December 18

New enforcement plan would target greatest potential harm
Type-2 diabetes patients most likely to pass on metformin
Delivery of care also likely to change, leaders tell Aon
Mouse study shows mature cells can create precancerous lesions

December 14

Monitoring the Future survey shows marijuana use remains common
Cream targets Staphylococcus aureus and Streptococcus pyogenes
Biotech companies, often younger and smaller, fare better
The company, which already sells Inflectra, got Ixifi in Hospira purchase

Pages